Novo Nordisk's cagrilintide shows promise in Phase 3 trial Alan Nafiev posted on the topic LinkedIn Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment